Search
forLearn
5 / 33 resultslearn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
learn Adenosine
nucleoside used for hair regrowth stimulant properties
learn Exosomes
Microscopic delivery system that sends growth-promoting signals to hair follicles
learn Latanoprost
glaucoma medication with hair follicle stimulant effects
Research
5 / 1000+ results
research Response to Ritlecitinib Treatment Based on Salt Improvement Scores in Patients With Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
Community Join
5 / 1000+ resultscommunity What is next for pp405 in phase 2b?
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
community Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.
community Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community Today was Last update on pp405
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.